Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 12.2% After Analyst Upgrade

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) shot up 12.2% during mid-day trading on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $32.00 to $36.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Day One Biopharmaceuticals traded as high as $17.39 and last […]

Leave a Reply

Your email address will not be published.

Previous post Market Impact: Analyzing Key Insights from PulteGroup Inc (PHM) SEC 10-Q Financial Filing
Next post Kimberly-Clark Corp. (KMB) Quarterly Report: What Does It Reveal About Their Sector Performance